In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novelion Therapeutics Inc.

https://ir.novelion.com/

Latest From Novelion Therapeutics Inc.

Access Bio’s CareStart Real Time PCR COVID-19 Test Earns EUA

The test, which can be processed in 83 minutes or less, has shown 100% sensitivity and 100% specificity in clinical trials, according to the New Jersey company.

Coronavirus COVID-19 In Vitro Diagnostics

SK Bio's 2020 Plans Undeterred By Pandemic

The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.

South Korea Business Strategies

Asia Deal Watch: Lupin Signs Up Three EU Marketing Partners For NaMuscla

Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.

Deals Business Strategies

SK Biopharm’s Hefty IPO To Support Novel Anti-Epileptic, Pipeline

SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.

South Korea Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aegerion Pharmaceuticals, Inc
    • QLT, Inc.
UsernamePublicRestriction

Register